Letter to the Editor
Split Viewer
Blood Res 2013; 48(1):
Published online March 31, 2013
https://doi.org/10.5045/br.2013.48.1.67
© The Korean Society of Hematology
Many questions raised by a question on JAK1/2 inhibitors in primary myelofibrosis
Institute of Haematology and Transfusion Medicine, KPC Medical College & Hospital, India.
Correspondence to : Lalit Raut. Institute of Haematology and Transfusion Medicine, KPC Medical College & Hospital, Jadavpur, Kolkata 700032, West Bengal, India. Tel: +919331717336, lalitraut76@yahoo.co.in
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
REFERENCES
- Jung, CW. Will JAK1/2 inhibitors change the standard of care for myelofibrosis?. Korean J Hematol, 2012;47;241-242.
- Verstovsek, S, Mesa, RA, Gotlib, J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med, 2012;366;799-807.
PDF
Standard view
Export citation
Share Article
Letter to the Editor
Blood Res 2013; 48(1): 67
Published online March 31, 2013 https://doi.org/10.5045/br.2013.48.1.67
Copyright © The Korean Society of Hematology.
Many questions raised by a question on JAK1/2 inhibitors in primary myelofibrosis
Lalit Raut, M.D.*
Institute of Haematology and Transfusion Medicine, KPC Medical College & Hospital, India.
Correspondence to: Lalit Raut. Institute of Haematology and Transfusion Medicine, KPC Medical College & Hospital, Jadavpur, Kolkata 700032, West Bengal, India. Tel: +919331717336, lalitraut76@yahoo.co.in
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
- Jung, CW. Will JAK1/2 inhibitors change the standard of care for myelofibrosis?. Korean J Hematol, 2012;47;241-242.
- Verstovsek, S, Mesa, RA, Gotlib, J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med, 2012;366;799-807.
Previous Article
